Drug Information

Drug (ID: DG01038) and It's Reported Resistant Information
Name
Vinpocetine
Synonyms
Vinpocetine; 42971-09-5; Cavinton; Ceractin; Apovincaminic acid ethyl ester; Ethyl apovincamin-22-oate; Bravinton; TCV-3B; Ethyl (+)-apovincaminate; Ultra-Vinca; RGH 4405; RGH-4405; cis-Apovincaminic acid ethyl ester; (+)-Apovincaminic acid ethyl ester; Ethyl (+)-cis-apovincaminate; (+)-cis-Apovincaminic acid ethyl ester; AY 27,255; TCV 3B; Ethyl apovincaminate; UNII-543512OBTC; 3-alpha,16-alpha-Apovincaminic acid ethyl ester; Eburnamenine-14-carboxylic acid ethyl ester; CHEMBL71752; MLS000069635; 543512OBTC; MFCD00211233; NSC-760093; (41S,13aS)-ethyl 13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate; NCGC00018204-09; Vinpocetinum; C22H26N2O2; SMR000058241; AY-27,255; Eburnamenine-14-carboxylic acid, ethyl ester, (3alpha,16alpha)-; DSSTox_CID_3740; DSSTox_RID_77176; DSSTox_GSID_23740; ethyl (41S,13aS)-13a-ethyl-2,3,41,5,6,13a-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate; Vinpocetinum [INN-Latin]; Eburnamenine-14-carboxylic acid, ethyl ester, (3a,16a)-; Apovincaminate d'ethyle; Vinporal; Apovincaminate d'ethyle [French]; 1H-Indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine, eburnamenine-14-carboxylic acid deriv.; SR-01000075633; EINECS 256-028-0; BRN 0900803; Vinpocetin; Vinpocetine (JAN/USAN/INN); Vinpocetine-ethyl apovincaminate; 3A,16A-Apovincaminic acid ethyl ester; NCGC00016854-03; Vinpocetine [USAN:INN:BAN:JAN]; Prestwick_963; Vinpocetin- Bio-X; CAS-42971-09-5; Spectrum_001400; Vinpocetine (Cavinton); AY 27255; SpecPlus_000327; Opera_ID_1325; Prestwick0_000268; Prestwick1_000268; Prestwick2_000268; Prestwick3_000268; Spectrum2_001529; Spectrum3_000961; Spectrum4_001075; Spectrum5_000966; V 6383; Lopac0_001257; SCHEMBL50081; BSPBio_000116; BSPBio_002561; KBioGR_001430; KBioSS_001880; MLS001076294; DivK1c_006423; SPECTRUM1503115; Vinpocetine, >=98%, solid; ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate; SPBio_001318; SPBio_002335; BPBio1_000128; cid_443955; GTPL5285; Vinpocetine, analytical standard; DTXSID5023740; REGID_for_CID_443955; CHEBI:32297; KBio1_001367; KBio2_001880; KBio2_004448; KBio2_007016; KBio3_001781; HMS1568F18; HMS1922G05; HMS2090J22; HMS2092L06; HMS2095F18; HMS3263L16; HMS3402D12; HMS3411H11; HMS3675H11; HMS3712F18; HMS3887E17; Pharmakon1600-01503115; (3alpha, 16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; 68780-77-8; AMY39087; BCP04123; Tox21_110648; Tox21_110839; Tox21_501257; BDBM50059033; CCG-39307; Eburnamenine-14-carboxylic acid, ethyl ester, (3-alpha,16-alpha)-; NSC760093; PD-185; s2110; ZINC19796031; AKOS015896480; Tox21_110648_1; CS-0545; DB12131; LP01257; NSC 760093; SDCCGSBI-0051224.P003; Vinpocetine 1.0 mg/ml in Acetonitrile; (3S,16S)-apovincaminic acid ethylester; NCGC00018204-05; NCGC00018204-06; NCGC00018204-07; NCGC00018204-08; NCGC00018204-10; NCGC00018204-11; NCGC00018204-13; NCGC00021727-04; NCGC00021727-05; NCGC00021727-06; NCGC00021727-07; NCGC00168782-01; NCGC00261942-01; NCGC00263865-01; NCGC00263865-04; AC-22612; AS-13868; AY-27255; BV164528; HY-13295; Eburnamenine-14-carboxylic acid ethyl ester;; EU-0101257; D01371; J10479; AB00052317_02; 971V095; Q420288; SR-01000000118; SR-01000000118-3; SR-01000075633-1; SR-01000075633-3; SR-01000075633-4; W-202748; BRD-K53318339-001-05-8; (3 ,16 )-Eburnamenine-14-carboxylic acid ethyl ester; Vinpocetine, European Pharmacopoeia (EP) Reference Standard; (3alpha,16alpha)-Eburnamenine-14-carboxylic acid ethyl ester; Vinpocetine, United States Pharmacopeia (USP) Reference Standard; (11aS,11bS)-11a-Ethyl-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthene-10-carboxylic acid ethyl ester; (3aS,11bS)-3a-ethyl-1,2,3,3a,10,11b-hexahydro-11H-5a,11a-diaza-benzo[cd]fluoranthene-5-carboxylic acid ethyl ester; 115986-87-3; 11a-Ethyl-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthene-10-carboxylic acid 2-nitrooxy-ethyl ester(Vinpocetine); ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.0^{2,7}.0^{8,18}.0^{15,19}]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate; ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
    Click to Show/Hide
Indication
In total 1 Indication(s)
Ischemic stroke [ICD-11: 8B11]
Approved
[1]
Structure
Target Phosphodiesterase 1 (PDE1) NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C22H26N2O2
IsoSMILES
CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC
InChI
1S/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1
InChIKey
DDNCQMVWWZOMLN-IRLDBZIGSA-N
PubChem CID
443955
ChEBI ID
CHEBI:32297
TTD Drug ID
D06BCB
INTEDE ID
DR1697
DrugBank ID
DB12131
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Liver cancer [ICD-11: 2C12]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Glycogen synthase kinase-3 beta (GSK3B) [1]
Molecule Alteration Function
Activation
 Molecule Info 
Sensitive Disease Hepatocellular carcinoma [ICD-11: 2C12.2]
 Disease Info 
Experimental Note Revealed Based on the Cell Line Data
Cell Pathway Regulation PI3K/AKT/GSK-3beta signaling pathway Activation hsa04931
In Vitro Model Saccharomyces cerevisiae strain 4932
Bacteroides thetaiotaomicron strain 818
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 Sulforhodamine blue (SRB) assay
Mechanism Description Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3beta signaling axis in hepatocellular carcinoma cells. Our study revealed that vinpocetine plus sorafenib could suppress the cytoprotective autophagy induced by vinpocetine and subsequently show synergistically anti-HCC activity via activating GSK-3beta and the combination of vinpocetine and sorafenib might reverse sorafenib resistance via the PI3K/protein kinase B/GSK-3beta signaling axis.
References
Ref 1 Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3Beta signaling axis in hepatocellular carcinoma cells .Anticancer Drugs. 2021 Aug 1;32(7):727-733. doi: 10.1097/CAD.0000000000001056. 10.1097/CAD.0000000000001056

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.